Verastem (VSTM) Short term Debt (2018 - 2024)

Verastem's (VSTM) quarterly Short term Debt came in at $9.9 million in Q3 2024, up 100.37% quarter-over-quarter from $4.9 million in Q2 2024.

Verastem (VSTM) Short term Debt (2018 - 2024) Analysis & Trends

Verastem's Short term Debt history runs 3 years deep, the most recent figure standing at $9.9 million for Q3 2024.

On a quarterly basis, Short term Debt changed N/A year-over-year to $9.9 million in Q3 2024; TTM through Sep 2024 was $9.9 million, a N/A change from a year earlier, with the FY2018 full-year figure at $5.7 million, changed N/A from the prior year.
Short term Debt rose to $9.9 million in Q3 2024 per VSTM's latest filing, from $4.9 million in the prior quarter.
Across five years, Short term Debt topped out at $9.9 million in Q3 2024 and bottomed at $4.6 million in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Verastem	166.09 Mn	-31.73 Mn	15.90 Mn

Download Data